Preprint Review Version 1 This version is not peer-reviewed

Meningococcal Vaccines: Current Status and Emerging Strategies

Version 1 : Received: 30 January 2018 / Approved: 31 January 2018 / Online: 31 January 2018 (03:07:42 CET)

A peer-reviewed article of this Preprint also exists.

McCarthy, P.C.; Sharyan, A.; Sheikhi Moghaddam, L. Meningococcal Vaccines: Current Status and Emerging Strategies. Vaccines 2018, 6, 12. McCarthy, P.C.; Sharyan, A.; Sheikhi Moghaddam, L. Meningococcal Vaccines: Current Status and Emerging Strategies. Vaccines 2018, 6, 12.

Journal reference: Vaccines 2018, 6, 12
DOI: 10.3390/vaccines6010012

Abstract

Neisseria meningitidis causes most cases of bacterial meningitis. Meningococcal meningitis is a public health burden to both developed and developing countries throughout the world. There are a number of vaccines (polysaccharide-based, glycoconjugate, protein-based and combined conjugate vaccines) that are approved to target five of the six disease-causing serogroups of the pathogen. Immunization strategies have been effective at helping to decrease the global incidence of meningococcal meningitis. Researchers continue to enhance these efforts through discovery of new antigen targets that may lead to a broadly protective vaccine and development of new methods of homogenous vaccine production. This review describes current meningococcal vaccines and discusses some recent research discoveries that may transform vaccine development against N. meningitidis in the future.

Subject Areas

Neisseria meningitidis; glycoconjugate vaccines; protein-based vaccines, vaccine development

Readers' Comments and Ratings (0)

Leave a public comment
Send a private comment to the author(s)
Rate this article
Views 0
Downloads 0
Comments 0
Metrics 0
Leave a public comment

×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.